Profound Medical Corp. (PROF) · Oct 7, 2026 · Earnings

Profound Medical Q3 earnings beat as revenue surges

Beat — Revenue $9.8–10.0M vs ~$6.78M consensus

Profound Medical’s preliminary Q3 earnings show revenue far above consensus, signaling stronger TULSA-PRO commercialization ahead of full results.

Profound is in the commercialization phase of its MRI-guided treatment platform, trying to turn a growing TULSA-PRO installed base into recurring procedure revenue while expanding new system placements. The installed base reached 84 systems in Q2, and management was already pointing to stronger second-half shipments, reimbursement expansion, and a roughly $25 million full-year 2026 revenue target.

The preliminary quarter is a clear revenue beat. Q3 revenue is expected at $9.8–10.0 million versus Bloomberg consensus of $6.78 million, or roughly 45%–47% above expectations. That is substantially more than a routine upside surprise and would make Q3 the company’s strongest quarter by a wide margin. *(Preliminary Financial Highlights)*

MeasureQ3 2026 preliminaryComparisonFiling source
Revenue$9.8M–$10.0M~$6.78M consensus; $5.3M in Q3 2025(Preliminary Financial Highlights)
Year-over-year growth85%–89%vs. Q3 2025(Preliminary Financial Highlights)
Sequential growth292%–300%vs. $2.5M in Q2 2026(Preliminary Financial Highlights)
Gross marginAbove 70%Company’s full-year target was at least 70%(Preliminary Financial Highlights)

The magnitude is partly less surprising than the headline. Q2 management had already disclosed that approximately $3.1 million of TULSA revenue recognition shifted into early Q3 because of shipment timing, so some rebound was expected. Even after allowing for that known timing effect, the preliminary range is far above the published consensus and points to additional contribution from new accounts or stronger commercial activity across the installed base. 〔0〕

The margin read supports the commercial-scale story, but the evidence is still incomplete. Gross margin is again expected to exceed 70%, matching the profitability threshold management set for 2026. 〔1〕 However, this is only preliminary revenue and gross-margin information; it does not yet show operating expenses, cash flow, net loss, or how much of the quarter came from capital-system sales versus recurring procedure-related revenue.

The next test is whether the quarter resets the full-year trajectory. Profound previously guided to approximately $25 million of 2026 revenue, and Q3’s preliminary result brings the first nine months to roughly $17.6–17.8 million using the company’s reported Q1 and Q2 figures. That would leave roughly $7.2 million needed in Q4 to reach the existing annual target—above its prior quarterly record—so the November release should clarify whether this is a durable acceleration or a shipment-heavy spike.

Bottom line: This is a genuine earnings beat that materially strengthens Profound’s commercialization story, even though some Q3 revenue was pulled forward from Q2. The full results matter because they will show whether the surge translated into recurring utilization and improved operating performance.

What to watch next

Full Q3 results and conference call, November 5

Original filing on SEC EDGAR

More Profound Medical Corp. news

Profound Medical Q3 earnings beat as revenue surges | PROF Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.